Global Apomorphine Hydrochloride Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Apomorphine Hydrochloride Market Research Report 2024
Apomorphine is a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors.
According to Mr Accuracy reports’s new survey, global Apomorphine Hydrochloride market is projected to reach US$ 364.1 million in 2034, increasing from US$ 277.7 million in 2024, with the CAGR of 3.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Apomorphine Hydrochloride market research.
The classification of Apomorphine Hydrochloride includes Injection, Tablets, Thinfilm, etc and the proportion of Injection in 2019 is about 89.88%, and the proportion is in decreasing trend from 2020 to 2025.
Apomorphine Hydrochloride is widely used through Parkinson Disease and Erectile Dysfunction. The most proportion of Apomorphine Hydrochloride is used for Parkinson Disease, and the sales proportion in 2019 is 89.88%.
Europe is the largest consumption place, with a consumption market share nearly 54.19% in 2019. Following Europe, North America is the second largest consumption place with the consumption market share of 23.69%.
Market competition is not intense. Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Apomorphine Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Supernus Pharmaceuticals
Britannia Pharmaceuticals STADA
Ever Pharma
Evolan Pharma AB (PharmSwed)
Tianjin Tianwei Pharmaceutical
Sunovion
Segment by Type
Injection
Tablets
Thinfilm
Nasal Powder (Pipeline)
Parkinson Disease
Erectile Dysfunction
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Apomorphine Hydrochloride report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Apomorphine Hydrochloride market is projected to reach US$ 364.1 million in 2034, increasing from US$ 277.7 million in 2024, with the CAGR of 3.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Apomorphine Hydrochloride market research.
The classification of Apomorphine Hydrochloride includes Injection, Tablets, Thinfilm, etc and the proportion of Injection in 2019 is about 89.88%, and the proportion is in decreasing trend from 2020 to 2025.
Apomorphine Hydrochloride is widely used through Parkinson Disease and Erectile Dysfunction. The most proportion of Apomorphine Hydrochloride is used for Parkinson Disease, and the sales proportion in 2019 is 89.88%.
Europe is the largest consumption place, with a consumption market share nearly 54.19% in 2019. Following Europe, North America is the second largest consumption place with the consumption market share of 23.69%.
Market competition is not intense. Supernus Pharmaceuticals, Britannia Pharmaceuticals STADA, Ever Pharma are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Apomorphine Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Supernus Pharmaceuticals
Britannia Pharmaceuticals STADA
Ever Pharma
Evolan Pharma AB (PharmSwed)
Tianjin Tianwei Pharmaceutical
Sunovion
Segment by Type
Injection
Tablets
Thinfilm
Nasal Powder (Pipeline)
Segment by Application
Parkinson Disease
Erectile Dysfunction
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Apomorphine Hydrochloride report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices